[Polychemotherapy with 5-(3,3 dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC; NSC-45388), 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC-409962) and vincristine (NSC-67574) in the metastatic phase of melanoma].
D000505:Alopecia / Q000139:chemically induced; D000577:Amides / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001855:Bone Marrow Diseases / Q000139:chemically induced; D002330:Carmustine / Q000009:adverse effects / Q000627:therapeutic use*; D004357:Drug Synergism; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D007970:Leukopenia / Q000139:chemically induced; D008545:Melanoma / Q000188:drug therapy*; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis / Q000188:drug therapy*; D012075:Remission, Spontaneous; D012878:Skin Neoplasms / Q000188:drug therapy*; D013280:Stomatitis / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced; D014226:Triazenes / Q000009:adverse effects / Q000627:therapeutic use*; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
D000577:Amides; D000970:Antineoplastic Agents; D007093:Imidazoles; D014226:Triazenes; D014750:Vincristine; D002330:Carmustine
Polichemioterapia con 5-(3,3 dimetil-1-triazeno)-imidazole-4-carboxamide (DTIC; NSC-45388), 1,3-bis (2-cloroetil)-1-nitrosourea (BCNU; NSC-409962) e vincristina (NSC-67574) nel melanoma in fase metastatizzata.